As of 2025-12-29, the EV/EBITDA ratio of EyePoint Pharmaceuticals Inc (EYPT) is -6.66. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. EYPT's latest enterprise value is 1,439.65 mil USD. EYPT's TTM EBITDA according to its financial statements is -216.25 mil USD. Dividing these 2 quantities gives us the above EYPT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.8x - 11.3x | 8.6x |
| Forward P/E multiples | 13.6x - 19.1x | 15.7x |
| Fair Price | (34.62) - (28.67) | (30.77) |
| Upside | -289.3% - -256.7% | -268.2% |
| Date | EV/EBITDA |
| 2025-12-26 | -6.66 |
| 2025-12-24 | -6.65 |
| 2025-12-23 | -6.69 |
| 2025-12-22 | -6.87 |
| 2025-12-19 | -6.33 |
| 2025-12-18 | -6.19 |
| 2025-12-17 | -6.03 |
| 2025-12-16 | -6.14 |
| 2025-12-15 | -5.93 |
| 2025-12-12 | -5.78 |
| 2025-12-11 | -5.82 |
| 2025-12-10 | -6.06 |
| 2025-12-09 | -6.19 |
| 2025-12-08 | -6.48 |
| 2025-12-05 | -6.45 |
| 2025-12-04 | -6.06 |
| 2025-12-03 | -5.21 |
| 2025-12-02 | -4.90 |
| 2025-12-01 | -5.11 |
| 2025-11-28 | -5.33 |
| 2025-11-26 | -5.32 |
| 2025-11-25 | -5.30 |
| 2025-11-24 | -5.17 |
| 2025-11-21 | -4.89 |
| 2025-11-20 | -4.88 |
| 2025-11-19 | -5.12 |
| 2025-11-18 | -5.00 |
| 2025-11-17 | -4.68 |
| 2025-11-14 | -4.09 |
| 2025-11-13 | -4.06 |
| 2025-11-12 | -4.25 |
| 2025-11-11 | -4.11 |
| 2025-11-10 | -4.00 |
| 2025-11-07 | -3.95 |
| 2025-11-06 | -3.90 |
| 2025-11-05 | -3.87 |
| 2025-11-04 | -4.40 |
| 2025-11-03 | -4.42 |
| 2025-10-31 | -4.67 |
| 2025-10-30 | -4.33 |
| 2025-10-29 | -4.15 |
| 2025-10-28 | -4.34 |
| 2025-10-27 | -4.29 |
| 2025-10-24 | -4.24 |
| 2025-10-23 | -4.06 |
| 2025-10-22 | -4.04 |
| 2025-10-21 | -4.18 |
| 2025-10-20 | -4.26 |
| 2025-10-17 | -4.11 |
| 2025-10-16 | -4.08 |